CD276 is highly expressed in bone during embryogenesis, and can be induced on dendritic cells and monocytes by inflammatory cytokines. CD276 has been implicated in the development of acute and chronic transplant rejection, and is reported to have therapeutic potential as a regulator of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy. In mice, CD276 has been linked with the development of pathogenic Th2 cells during the induction phase of allergic asthma.
Pathway
Adipogenesis; Alzheimer's disease; Chylomicron-mediated lipid transport; Developmental Biology; Disease; Diseases associated with visual transduction; Fatty Acid Beta Oxidation; Glycerolipid metabolism; Lipid digestion, mobilization, and transport; Lipoprotein metabolism; Metabolism; Metabolism of lipids and lipoproteins; PPAR signaling pathway; Retinoid metabolism and transport; Signal Transduction; Statin Pathway; Transcriptional Regulation of White Adipocyte Differentiation; Triacylglyceride
Citations
Publication ()
Have you cited DCABY-578 in a publication? Let us know and earn a reward for your research.
My Review for Anti-CD276 monoclonal antibody, clone NK9 [FITC]
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
